On July 30, XTALPI fell 5.15% in regular trading, trading at 6.45 HKD/share, with turnover of HKD 260 million. The decline extends a multi-day selloff triggered by the company's profit warning issued on July 24.

According to the profit warning, XTALPI expects a net loss attributable to shareholders of RMB 215 million to RMB 275 million for the first half, compared with a net profit of RMB 82.8 million in the year-earlier period, representing a swing from profit to loss. Revenue is expected at RMB 380 million to RMB 400 million, down from RMB 517.1 million a year ago, primarily due to the absence of a USD 51 million upfront payment from the DoveTree pipeline licensing project recognized in the prior-year period. Additionally, R&D expenses are expected to be no less than RMB 340 million, up over 50% year-on-year, driven by continued investment in autonomous laboratories, agentic systems, and drug development programs, further compressing profitability.

Within the Life Sciences Tools and Services sector, the broader sector declined. Among peers, WUXI BIO fell 5.69%, WUXI XDC fell 5.89%, INSILICO fell 5.52%, WUXI APPTEC fell 3.78%, and GENSCRIPT BIO fell 2.53%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)